- Home
- CERO vs ISPC Comparison
CERO vs ISPC Comparison
Compare CERO & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- ISPC
- Stock Information
- Founded
- CERO 2017
- ISPC 2009
- Country
- CERO United States
- ISPC United States
- Employees
- CERO N/A
- ISPC N/A
- Industry
- CERO
- ISPC Precision Instruments
- Sector
- CERO
- ISPC Health Care
- Exchange
- CERO Nasdaq
- ISPC Nasdaq
- Market Cap
- CERO 3.5M
- ISPC 3.1M
- IPO Year
- CERO N/A
- ISPC 2021
- Fundamental
- Price
- CERO $7.50
- ISPC $1.10
- Analyst Decision
- CERO Strong Buy
- ISPC
- Analyst Count
- CERO 2
- ISPC 0
- Target Price
- CERO $45.00
- ISPC N/A
- AVG Volume (30 Days)
- CERO 95.7K
- ISPC 190.8K
- Earning Date
- CERO 08-13-2025
- ISPC 08-05-2025
- Dividend Yield
- CERO N/A
- ISPC N/A
- EPS Growth
- CERO N/A
- ISPC N/A
- EPS
- CERO N/A
- ISPC N/A
- Revenue
- CERO N/A
- ISPC $8,058,631.00
- Revenue This Year
- CERO N/A
- ISPC $35.93
- Revenue Next Year
- CERO N/A
- ISPC N/A
- P/E Ratio
- CERO N/A
- ISPC N/A
- Revenue Growth
- CERO N/A
- ISPC N/A
- 52 Week Low
- CERO $6.71
- ISPC $0.86
- 52 Week High
- CERO $895.40
- ISPC $8.30
- Technical
- Relative Strength Index (RSI)
- CERO 40.75
- ISPC 54.22
- Support Level
- CERO $7.27
- ISPC $0.90
- Resistance Level
- CERO $8.83
- ISPC $1.14
- Average True Range (ATR)
- CERO 0.43
- ISPC 0.14
- MACD
- CERO -0.06
- ISPC 0.01
- Stochastic Oscillator
- CERO 13.14
- ISPC 58.82
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.